THC and Amphetamine Tolerance Did Not Share One Distribution Explanation in a Rat Study

A 1976 rat study compared tolerance to THC and amphetamine alongside drug distribution in brain fractions. Its authors proposed different explanations for the two drugs, illustrating why tolerance does not identify one common distribution mechanism.

Peak intensity and duration were different observations

After repeated THC administration, the initial response was approximately similar to that after one injection, while the effect disappeared during the subsequent observation period. A shorter effect is not necessarily a weaker peak, and the distinction changes what tolerance means in this context.

The study compared another drug under another regimen

Amphetamine tolerance was not associated with reduced unchanged-drug accumulation in the sampled subcellular fractions. That contrast did not establish one universal mechanism for either drug. Regimens and analytical measures differed, and the conclusions remain conditional.

Radiolabel measurements require chemical identity

The THC investigation assessed specific activities associated with labeled THC and its metabolites in brain fractions. A radiolabel-derived distribution is not automatically a selective measure of active parent drug or receptor occupancy. The authors' metabolic account should not be converted into a general rule about all THC tolerance.

Interpreting the evidence

The useful result separates effect duration, initial intensity and measured distribution. This historical animal study does not establish a human clearance rate or show that shorter observed effects necessarily mean lower impairment at every point after use.

Related reading: interpreting cannabis tolerance claims.

Research reference

Magour S; Coper H; Fähndrich C (1976). An attempt to correlate the development of tolerance to delta-9-tetrahydrocannabinol and d-amphetamine with their subcellular distribution in rat brain. Polish journal of pharmacology and pharmacy. PubMed research record.

This analysis draws on the supplied abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us